BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
高成長
同社の収益は過去3年間にわたり着実に増加しており、年平均で26.84%の成長率を示しています。
成長中
同社は成長フェーズにあり、最新の年間収益はUSD 96.21Mに達しています。
割安
同社の最新のPEは-451.57で、過去3年間の水準と比較して安値圏にあります。
機関投資家の売り越し
最新の機関投資家の保有株数は51.34M株で、前四半期比で2.40%減少しています。
市場活動が活発
同社への投資家の関心が高まっており、20日間の売買回転率は1.41です。